Ten‐Year Outcome of Recanalization or Medical Therapy for Concomitant Chronic Total Occlusion After Myocardial Infarction
Open Access
- 21 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (10) , e033556
Abstract
Background: The EXPLORE (Evaluating Xience and Left Ventricular Function in PCI on Occlusions After STEMI) trial was the first and only randomized trial investigating chronic total occlusion (CTO) percutaneous coronary intervention (PCI) early after primary PCI for ST‐segment–elevation myocardial infarction, compared with medical therapy for the CTO. We performed a 10‐year follow‐up of EXPLORE to investigate long‐term safety and clinical impact of CTO PCI after ST‐segment–elevation myocardial infarction, compared with no‐CTO PCI. Methods and Results: In EXPLORE, 302 patients post‐ST‐segment–elevation myocardial infarction with concurrent CTO were randomized to CTO PCI within ≈1 week or no‐CTO PCI. We performed an extended clinical follow‐up for the primary end point of major adverse cardiac events, consisting of cardiovascular death, coronary artery bypass grafting, or myocardial infarction. Secondary end points included all‐cause death, angina, and dyspnea. Median follow‐up was 10 years (interquartile range, 8–11 years). The primary end point occurred in 25% of patients with CTO PCI and in 24% of patients with no‐CTO PCI (hazard ratio [HR], 1.11 [95% CI, 0.70–1.76]). Cardiovascular mortality was higher in the CTO PCI group (HR, 2.09 [95% CI, 1.10–2.50]), but all‐cause death was similar (HR, 1.53 [95% CI, 0.93–2.50]). Dyspnea relief was more frequent after CTO PCI (83% versus 65%, P =0.005), with no significant difference in angina. Conclusions: This 10‐year follow‐up of patients post‐ST‐segment–elevation myocardial infarction randomized to CTO PCI or no‐CTO PCI demonstrated no clinical benefit of CTO PCI in major adverse cardiac events or overall mortality. However, CTO PCI was associated with a higher cardiovascular mortality compared with no‐CTO PCI. Our long‐term data support a careful weighing of effective symptom relief against an elevated cardiovascular mortality risk in CTO PCI decisions. Registration: URL: https://www.trialregister.nl ; Unique identifier: NTR1108.Keywords
This publication has 35 references indexed in Scilit:
- International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and designAmerican Heart Journal, 2022
- Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: a systematic review and meta-analysis of randomised trialsNetherlands Heart Journal, 2020
- Recovery of myocardial perfusion after percutaneous coronary intervention of chronic total occlusions is comparable to hemodynamically significant non‐occlusive lesionsCatheterization and Cardiovascular Interventions, 2018
- A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total OcclusionJACC: Cardiovascular Interventions, 2018
- The IMPACTOR-CTO TrialJACC: Cardiovascular Interventions, 2018
- Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMIJACC, 2016
- CMR Guidance for Recanalization of Coronary Chronic Total OcclusionJACC: Cardiovascular Imaging, 2016
- Changes in myocardial ischemic burden following percutaneous coronary intervention of chronic total occlusionsCatheterization and Cardiovascular Interventions, 2011
- Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term Mortality and Left Ventricular Function in Patients After Primary Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2009
- Optimal Medical Therapy with or without PCI for Stable Coronary DiseaseNew England Journal of Medicine, 2007